Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells - PubMed (original) (raw)

. 2012 Oct 1;18(19):5374-86.

doi: 10.1158/1078-0432.CCR-12-0736. Epub 2012 Sep 5.

Marcus M Fischer, Mark Hynes, Jingjiang Wu, Edward Kim, Lucia Beviglia, V Pete Yeung, Xiaomei Song, Ann M Kapoun, John Lewicki, Austin Gurney, Diane M Simeone, Timothy Hoey

Affiliations

• PMID: 22952347
• DOI: 10.1158/1078-0432.CCR-12-0736

Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells

Wan-Ching Yen et al. Clin Cancer Res. 2012.

Abstract

Purpose: We previously showed that targeting Delta-like ligand 4 (DLL4) in colon and breast tumors inhibited tumor growth and reduced tumor initiating cell frequency. In this report, we have extended these studies to pancreatic cancer and probed the mechanism of action in tumor and stromal cells involved in antitumor efficacy.

Experimental design: Patient-derived pancreatic xenograft tumor models were used to evaluate the antitumor effect of anti-DLL4. To investigate the mechanism of action, we compared the activity of targeting DLL4 in tumor cells with an anti-human DLL4 antibody (anti-hDLL4) and in the host stroma/vasculature with an anti-mouse DLL4 antibody (anti-mDLL4). The effect of these antibodies on cancer stem cell frequency was examined by in vivo limiting dilution assays.

Results: The combination of anti-hDLL4 and anti-mDLL4 was efficacious in a broad spectrum of pancreatic tumor xenografts and showed additive antitumor activity together with gemcitabine. Treatment with either anti-hDLL4 or anti-mDLL4 delayed pancreatic tumor recurrence following termination of gemcitabine treatment, and the two together produced an additive effect. Anti-hDLL4 had a pronounced effect in reducing the tumorigenicity of pancreatic cancer cells based on serial transplantation and tumorsphere assays. In contrast, disruption of tumor angiogenesis with anti-mDLL4 alone or with anti-VEGF had minimal effects on tumorigenicity. Gene expression analyses indicated that anti-DLL4 treatment regulated genes that participate in Notch signaling, pancreatic differentiation, and epithelial-to-mesenchymal transition.

Conclusions: Our findings suggest a novel therapeutic approach for pancreatic cancer treatment through antagonism of DLL4/Notch signaling.

PubMed Disclaimer

Similar articles

• Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
  Kim DH, Lee S, Kang HG, Park HW, Lee HW, Kim D, Yoem DH, Ahn JH, Ha E, You WK, Lee SH, Kim SJ, Chun KH. Kim DH, et al. BMB Rep. 2020 Nov;53(10):533-538. doi: 10.5483/BMBRep.2020.53.10.103. BMB Rep. 2020. PMID: 32580836 Free PMC article.
• Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
  Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, Biswas S, Turley H, Heikamp E, Hainfellner JA, Harris AL. Li JL, et al. Cancer Res. 2007 Dec 1;67(23):11244-53. doi: 10.1158/0008-5472.CAN-07-0969. Cancer Res. 2007. PMID: 18056450
• Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
  Kuhnert F, Chen G, Coetzee S, Thambi N, Hickey C, Shan J, Kovalenko P, Noguera-Troise I, Smith E, Fairhurst J, Andreev J, Kirshner JR, Papadopoulos N, Thurston G. Kuhnert F, et al. Cancer Res. 2015 Oct 1;75(19):4086-96. doi: 10.1158/0008-5472.CAN-14-3773. Epub 2015 Sep 16. Cancer Res. 2015. PMID: 26377940
• Delta-like 4/Notch signaling and its therapeutic implications.
  Yan M, Plowman GD. Yan M, et al. Clin Cancer Res. 2007 Dec 15;13(24):7243-6. doi: 10.1158/1078-0432.CCR-07-1393. Clin Cancer Res. 2007. PMID: 18094402 Review.
• Notch signaling regulates tumor angiogenesis by diverse mechanisms.
  Dufraine J, Funahashi Y, Kitajewski J. Dufraine J, et al. Oncogene. 2008 Sep 1;27(38):5132-7. doi: 10.1038/onc.2008.227. Oncogene. 2008. PMID: 18758482 Free PMC article. Review.

Cited by

• The Prediction of DLL4 as a Prognostic Biomarker in Patients with Gastric Cancer Using Anti-DLL4 Nanobody.
  Afzalipour R, Abbasi-Dokht T, Sheikh M, Mohammadlou M, Nili F, Baharlou R. Afzalipour R, et al. J Gastrointest Cancer. 2024 Sep;55(3):1380-1387. doi: 10.1007/s12029-024-01093-9. Epub 2024 Jul 24. J Gastrointest Cancer. 2024. PMID: 39046662
• The differential distributions of ASPM isoforms and their roles in Wnt signaling, cell cycle progression, and pancreatic cancer prognosis.
  Hsu CC, Liao WY, Chan TS, Chen WY, Lee CT, Shan YS, Huang PJ, Hou YC, Li CR, Tsai KK. Hsu CC, et al. J Pathol. 2019 Dec;249(4):498-508. doi: 10.1002/path.5341. Epub 2019 Oct 23. J Pathol. 2019. PMID: 31465125 Free PMC article.
• Notch signaling pathway in cancer: from mechanistic insights to targeted therapies.
  Shi Q, Xue C, Zeng Y, Yuan X, Chu Q, Jiang S, Wang J, Zhang Y, Zhu D, Li L. Shi Q, et al. Signal Transduct Target Ther. 2024 May 27;9(1):128. doi: 10.1038/s41392-024-01828-x. Signal Transduct Target Ther. 2024. PMID: 38797752 Free PMC article. Review.
• Promising molecular mechanisms responsible for gemcitabine resistance in cancer.
  Jia Y, Xie J. Jia Y, et al. Genes Dis. 2015 Jul 30;2(4):299-306. doi: 10.1016/j.gendis.2015.07.003. eCollection 2015 Dec. Genes Dis. 2015. PMID: 30258872 Free PMC article. Review.
• DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
  Drouillard A, Puleo F, Bachet JB, Ouazzani S, Calomme A, Demetter P, Verset G, Van Laethem JL, Maréchal R. Drouillard A, et al. Br J Cancer. 2016 Nov 8;115(10):1245-1252. doi: 10.1038/bjc.2016.319. Epub 2016 Oct 18. Br J Cancer. 2016. PMID: 27755532 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information